
Anaconda Biomed is a Spanish medical device company developing funnel catheter technology for stroke treatment.
Anaconda Biomed, S.L. is a medical device company headquartered in Sant Quirze del Vallès, Barcelona, Spain, focused on next-generation endovascular access and protection in neurovascular care. Its funnel catheter platform is designed for mechanical thrombectomy in large vessel occlusion ischemic stroke, combining high-efficiency aspiration, controlled flow arrest, and clot capture in a self-expanding nitinol funnel. The lead product, the ANA5 Funnel Catheter, carries CE marking for European distribution and is studied in United States clinical trials, where it remains investigational.
The company was co-founded by Marc Ribó and Ofir Arad and operates its own development and manufacturing near Barcelona. Its clinical program includes the ATHENA randomized pivotal trial in the United States and earlier published results of the ANAIS study of the funnel catheter. Backers include international and Spanish life science investors such as Omega Funds, Asabys Partners, and Ysios Capital.
Palmera Medical

Bi02 Medical
bio2medical.com

Advanced Catheter Therapies
acatheter.com

NeuRx Medical
neurxmed.com

Captor Medical
captormedical.com

Q'Apel Medical
qapelmedical.com

Vena Medical
venamed.ca

Mivi Neuroscience
mivineuro.com

Cognition Medical

XCath

Rapidpulse
rapidpulsemed.com

Capture Vascular

Conformal Medical

Thrombolex
thrombolex.com

TuCann Medical
tucannmedical.co
Companies similar to Anaconda Biomed include Palmera Medical, Bi02 Medical, Advanced Catheter Therapies and NeuRx Medical.
Anaconda Biomed was founded in 2015.
Anaconda Biomed's headquarters is located in Sant Quirze del Vallès, Barcelona, ES.
Anaconda Biomed's most recent funding round was for $56M (USD) in September 2026.
As of Sep 23, 2026, Anaconda Biomed has raised a total of 66M.
Anaconda Biomed has 44 employees as of Sep 30, 2026.